Under-The-Radar Biotech Profile (Nasdaq: ONCO) Tops Thursday's Watchlist (Low Float)

The spotlight is shifting in the markets...

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Under-The-Radar Biotech Profile (Nasdaq: ONCO) Tops Thursday's Watchlist (Low Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* February 11th Greetings, Friend! The spotlight is shifting in the markets... While big pharma captures headlines, under-the-radar biotech companies are quietly making breakthroughs that could redefine their industries. These innovators are flying low today, but their potential impact is too big to ignore. Now might be the moment to look where few others are watching. And following a burst which saw this profile rocket 30% intraday from its open to its high Wednesday, potentially created from the dynamics of having a very low float, it appears that this little-known Nasdaq biotech idea could be starting to attract serious attention. Let us introduce you to: Onconetix, Inc. (Nasdaq: ONCO) Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through their acquisition of Proteomedix, the Company owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR. Developing A Specialized Platform For Prostate Health Onconetix, Inc. is a commercial-stage biotechnology company headquartered in Cincinnati, Ohio, that was formed through the strategic combination of Blue Water Biotech and Proteomedix. Unlike many organizations that focus exclusively on either development or medical testing, ONCO operates a diversified portfolio that spans the entire patient journey. Their mission is to improve how prostate conditions—ranging from non-cancerous enlargement to aggressive malignancies—are identified, evaluated, and managed by clinicians. The company’s distinctive value lies in its integrated approach. By housing both an FDA-approved therapeutic and a clinically validated diagnostic under one roof, ONCO aims to capture value at multiple points of the prostate disease pathway. This "personalized medicine" model is designed to reduce the high rate of unnecessary procedures and provide targeted relief for common symptoms, addressing a market that continues to grow as the global population ages. Recent milestones have transitioned the company from a developmental entity into an active commercial player. The commercial launch of their lead therapeutic product and the expansion of their diagnostic testing through major laboratory partnerships mark a significant turning point in the company's operational history. The Synergistic Strategy: Pairing Therapeutics With Diagnostics Addressing the BPH Burden with ENTADFI®. The therapeutic pillar of ONCO is led by ENTADFI®, an FDA-approved, once-daily oral capsule for the treatment of benign prostatic hyperplasia (BPH). BPH is a non-cancerous enlargement of the prostate that affects a vast majority of men over age 50, often leading to debilitating urinary symptoms. ENTADFI® combines two established agents into a single capsule, and clinical data indicates it offers superior improvements in urinary flow and quality of life compared to finasteride alone. By simplifying the treatment regimen and enhancing efficacy, ONCO is targeting a massive primary care and urology market. Clarifying Cancer Decisions with PROCLARIX® On the diagnostic side, PROCLARIX® is a next-generation blood test designed to help doctors estimate the likelihood of clinically significant prostate cancer. It is specifically positioned as a companion to standard PSA testing, which is notorious for producing "gray zone" results that often lead to unnecessary and invasive biopsies. PROCLARIX® utilizes a proprietary algorithm to analyze blood markers, providing a risk score that helps clinicians decide whether a biopsy is truly necessary. The test is already CE-IVDR certified in Europe and is available in the U.S. as a lab-developed test through an exclusive partnership with Labcorp.  Grab Sources And More: ONCO Website. ONCO Presentation. ----- 5 Explosive Potential Catalysts Put (Nasdaq: ONCO) On Radar Watch #1. ONCO Has A Very Low Float (Volatility Potential Could Be Explosive). With a float of roughly 1.24Mn shares, according to the Yahoo Finance website, volatility potential could pop up in a flash. #2. Chart Support May Be Strengthening At 4 Key Technical Levels. ONCO ended Wednesday's session in a noteworthy spot on its chart. The Nasdaq profile closed above four important technical levels suggesting that chart support may be gaining momentum. The 4 technical levels that could be building strength: 20-Day Simple Moving Average (SMA) 50-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA #3. Onconetix Announces Its Subsidiary, Proteomedix, Licenses Manufacturing IP To Immunovia Enabling Them To Independently Produce Key Reagents For Their Pancreatic Cancer Test PancreaSureTM. Onconetix, Inc. reported its subsidiary Proteomedix AG licensed manufacturing IP and master cells to Immunovia AB, enabling independent production of reagents for the PancreaSure pancreatic cancer test. The agreement covers antibodies for three of PancreaSure’s five biomarkers and related IP, allowing Immunovia to source reagents directly from Proteomedix. Immunovia will pay Proteomedix $700k in 2025–2026 and a 3% royalty on PancreaSure net sales and related products from 2026–2032. Proteomedix and Onconetix emphasize accelerated, accessible early detection and continued prostate cancer efforts with Proclarix. #4. Onconetix Announces Successful Clinical Validation Of Its Innovative Prostate Cancer Test Proclarix In A Danish Cohort. Onconetix, Inc. announced positive clinical validation results for its advanced prostate cancer diagnostic test, Proclarix®, in a Danish cohort presented at the 2025 European Association of Urology Congress. The study of 808 patients confirmed Proclarix’s high sensitivity (96%) and superior specificity compared with %fPSA and the ERSPC risk calculator. In patients with enlarged prostates, Proclarix reduced unnecessary biopsies by 22% while maintaining reliable cancer detection. These results highlight Proclarix’s value in improving diagnostic accuracy, minimizing overtreatment, and supporting Onconetix’s mission to advance global oncology care. #5. Onconetix Announces New Clinical Data For Its Innovative Prostate Cancer Test Proclarix Accepted For Presentation At 2025 European Association Of Urology Congress. Onconetix, Inc. announced that clinical data for its innovative prostate cancer test, Proclarix®, was accepted for presentation at the 2025 European Association of Urology Congress in Madrid. The study, involving more than 800 Danish patients, demonstrated Proclarix’s strength in distinguishing clinically significant prostate cancer from low-risk or non-cancer cases. This recognition underscores Onconetix’s scientific credibility and leadership in precision oncology, as Proclarix continues to prove effective in reducing unnecessary biopsies and improving diagnostic confidence in early prostate cancer detection worldwide. ----- Coverage is officially underway on Onconetix, Inc. (Nasdaq: ONCO). Be on the lookout for updates coming your way shortly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 02/11/2026 and ending on 02/12/2026 to publicly disseminate information about (ONCO:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC eight thousand USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ONCO:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/onco-o2se5/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice